1. A combination comprising (i) compounds of structure (I) or a pharmaceutically acceptable salt or solvate thereof (ii) cetuximab and optionally comprising, (iii) compounds of structure (II) or a pharmaceutically acceptable sol.2. Combination according to Claim. 1, wherein the compound (I) is in the form of dimethyl sulfoxide solvate, a compound (II) is in the form of the methanesulfonate soli.3. A combination comprising: (i) compounds of structure (I) or a pharmaceutically acceptable salt or solvate thereof and (ii) tsetuksimab.4. A combination comprising: (i) compounds of structure (II) or a pharmaceutically acceptable salt or solvate thereof and (ii) tsetuksimab.5. Combined kit or pharmaceutical composition comprising a combination according to any one of claims. 1-4 together with a pharmaceutically acceptable carrier or nositelyami.6. Combination according to any one of claims. 1-5 for use in therapy or for use in treating malignant novoobrazovaniya.7. Combination according to Claim. 1 for use in treating malignant novoobrazovaniya.8. Combination according to Claim. 1 wherein cetuximab is administered in an amount of 400 mg / gsm to 250 mg / m, 9. Combination according to Claim. 1 for use according to claim. 8, wherein cetuximab is administered in an amount of about 400 mg / m inputted to a 2-hour intravenous infusion, or wherein cetuximab is administered in an amount of 250 mg / m inputted via infusion over 1 chasa.10. Combination according to Claim. 1 for use according to any one of claims. 7-9, wherein cetuximab is administered together with a compound of Structure I or a pharmaceutically acceptable salt or solvate thereof and a compound of Structure II or a pharmaceutically acceptable solyu.11. Combination according to Claim. 1 for use according to any one of claims. 7-10, wherein the cancer is selected from malignant tumors, head and neck, breast, cancer1. Комбинация, содержащая(i) соединение Структуры (I)или его фармацевтически приемлемую соль или сольват
